Intravitreal antivascular endothelial growth factor therapy may induce proteinuria and antibody mediated injury in renal allografts

Transplantation

Volumn 99, Issue 11, 2015, Pages 2382-2386

  Cheungpasitporn, Wisit ^a   Chebib, Fouad T ^a   Cornell, Lynn D ^a   Brodin, Michelle L ^a   Nasr, Samih H ^a   Schinstock, Carrie A ^a   Stegall, Mark D ^a   Amer, Hatem ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CREATININE; MYCOPHENOLATE MOFETIL; PHOSPHOLIPASE A2 RECEPTOR; PREDNISONE; RANIBIZUMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANGIOMYOLIPOMA; ANTIBODY MEDIATED REJECTION; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; END STAGE RENAL DISEASE; GLOMERULONEPHRITIS; GLOMERULOPATHY; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY ATROPHY; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY POLYCYSTIC DISEASE; MALE; MEDICAL HISTORY; MEMBRANOUS GLOMERULONEPHRITIS; MIDDLE AGED; PRIORITY JOURNAL; PROTEINURIA; RENAL GRAFT DYSFUNCTION; TUBEROUS SCLEROSIS; ALLOGRAFT; ANTAGONISTS AND INHIBITORS; BIOPSY; CHEMICALLY INDUCED; DRUG EFFECTS; ELECTRON MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; GRAFT REJECTION; IMMUNOLOGY; INTRAVITREAL DRUG ADMINISTRATION; KIDNEY; KIDNEY TRANSPLANTATION; MACULAR DEGENERATION; METABOLISM; RISK FACTOR; TIME; ULTRASTRUCTURE;

AGED; ALLOGRAFTS; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BIOPSY; FLUORESCENT ANTIBODY TECHNIQUE; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMANS; INTRAVITREAL INJECTIONS; KIDNEY; KIDNEY TRANSPLANTATION; MACULAR DEGENERATION; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; PROTEINURIA; RANIBIZUMAB; RISK FACTORS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84945905517     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000750     Document Type: Article

References (22)

1. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65: 2003-2017.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005; 438:932-936.
3. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005;3:25-33.
4. Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature. 2005;438:960-966.
5. Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156:15-22e1.
6. Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology. 2007;114:1702-1712.
7. Naresh CN, Hayen A, Weening A, et al. Day-to-day variability in spot urine albumin-creatinine ratio. Am J Kidney Dis. 2013;62:1095-1101.
8. Kowalewska J, Smith KD, Hudkins KL, et al. Membranous glomerulopathy with spherules: an uncommon variant with obscure pathogenesis. Am J Kidney Dis. 2006;47:983-992.
9. Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant. 2012;12:563-570.
10. El-Zoghby ZM, Grande JP, Fraile MG, et al. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant. 2009;9:2800-2807.
11. Herrmann SM, Sethi S, Fervenza FC. Membranous nephropathy: the start of a paradigm shift. Curr Opin Nephrol Hypertens. 2012;21:203-210.
12. Myslak M, Amer H, Morales P, et al. Interpreting post-transplant proteinuria in patients with proteinuria pre-transplant. Am J Transplant. 2006;6:1660-1665.
13. D'Cunha PT, Parasuraman R, Venkat KK. Rapid resolution of proteinuria of native kidney origin following live donor renal transplantation. Am J Transplant. 2005;5:351-355.
14. Jimenez-Sousa MA, Fernandez-Rodriguez A, Heredia M, et al. Genetic polymorphisms located in TGFB1, AGTR1, and VEGFA genes are associated to chronic renal allograft dysfunction. Cytokine. 2012;58: 321-326.
15. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278:12605-12608.
16. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707-716.
17. Ko HT, Yin JL, Wyburn K, et al. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction. Nephrol Dial Transplant. 2013;28:327-336.
18. Georgalas I, Papaconstantinou D, Papadopoulos K, et al. Renal injury following intravitreal anti-VEGF administration in diabetic patients with proliferative diabetic retinopathy and chronic kidney disease-a possible side effect? Curr Drug Saf. 2014;9:156-158.
19. Alvarez Arroyo MV, Suzuki Y, Yague S, et al. Role of endogenous vascular endothelial growth factor in tubular cell protection against acute cyclosporine toxicity. Transplantation. 2002;74:1618-1624.
20. Peng W, Chen J, Jiang Y, et al. Acute renal allograft rejection is associated with increased levels of vascular endothelial growth factor in the urine. Nephrology. 2008;13:73-79.
21. Bieri M, Oroszlan M, Farkas A, et al. Anti-HLA I antibodies induce VEGF production by endothelial cells, which increases proliferation and paracellular permeability. Int J Biochem Cell Biol. 2009;41:2422-2430.
22. Mittal RD, Srivastava P, Singh V, et al. Association of common variants of vascular endothelial growth factor and interleukin-18 genes with allograft survival in renal transplant recipients of North India. DNA Cell Biol. 2011;30:309-315.